StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to Buy

Esperion Therapeutics (NASDAQ:ESPR) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Thursday.

A number of other brokerages also recently issued reports on ESPR. Needham & Company LLC dropped their price target on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Monday, August 12th. Finally, Bank of America downgraded Esperion Therapeutics from a “neutral” rating to an “underperform” rating and dropped their price target for the company from $2.90 to $2.50 in a research report on Thursday, June 20th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Esperion Therapeutics has an average rating of “Hold” and a consensus price target of $8.17.

Esperion Therapeutics Stock Down 4.0 %

Shares of NASDAQ ESPR opened at $1.68 on Thursday. Esperion Therapeutics has a 52 week low of $0.70 and a 52 week high of $3.40. The business has a 50-day simple moving average of $1.99 and a two-hundred day simple moving average of $2.23. The company has a market cap of $318.29 million, a P/E ratio of -1.70 and a beta of 1.00.

Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.10. The company had revenue of $73.83 million during the quarter, compared to the consensus estimate of $51.90 million. Equities research analysts anticipate that Esperion Therapeutics will post -0.04 EPS for the current year.

Hedge Funds Weigh In On Esperion Therapeutics

A number of large investors have recently modified their holdings of the company. Capital Advisors Wealth Management LLC raised its holdings in shares of Esperion Therapeutics by 22.9% during the 2nd quarter. Capital Advisors Wealth Management LLC now owns 26,800 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 5,000 shares in the last quarter. Summit Financial LLC raised its holdings in shares of Esperion Therapeutics by 26.4% during the 2nd quarter. Summit Financial LLC now owns 32,687 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 6,823 shares in the last quarter. National Bank of Canada FI increased its stake in Esperion Therapeutics by 115.9% in the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 10,225 shares during the period. GSA Capital Partners LLP increased its stake in Esperion Therapeutics by 1.0% in the 4th quarter. GSA Capital Partners LLP now owns 1,128,149 shares of the biopharmaceutical company’s stock worth $3,373,000 after purchasing an additional 11,494 shares during the period. Finally, SG Americas Securities LLC increased its stake in Esperion Therapeutics by 45.3% in the 2nd quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 11,658 shares during the period. 47.39% of the stock is owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.